Summit Therapeutics (SMMT) Non-Current Receivables (2021 - 2024)
Summit Therapeutics (SMMT) has disclosed Non-Current Receivables for 4 consecutive years, with $698000.0 as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Non-Current Receivables fell 27.22% year-over-year to $698000.0, compared with a TTM value of $698000.0 through Dec 2024, down 27.22%, and an annual FY2024 reading of $698000.0, down 27.22% over the prior year.
- Non-Current Receivables was $698000.0 for Q4 2024 at Summit Therapeutics, up from $467000.0 in the prior quarter.
- Across five years, Non-Current Receivables topped out at $11.3 million in Q3 2021 and bottomed at $212000.0 in Q1 2024.
- Average Non-Current Receivables over 4 years is $2.4 million, with a median of $747000.0 recorded in 2023.
- The sharpest move saw Non-Current Receivables plummeted 77.92% in 2023, then fell 27.22% in 2024.
- Year by year, Non-Current Receivables stood at $11.3 million in 2021, then crashed by 70.79% to $3.3 million in 2022, then crashed by 70.95% to $959000.0 in 2023, then dropped by 27.22% to $698000.0 in 2024.
- Business Quant data shows Non-Current Receivables for SMMT at $698000.0 in Q4 2024, $467000.0 in Q3 2024, and $364000.0 in Q2 2024.